ursolic acid has been researched along with Clinically Isolated CNS Demyelinating Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bakhtiari, N; Hojati, V; Honarvar, F; Javan, M; Zare, L | 1 |
| Iwasa, K; Maruyama, K; Sakemoto, C; Shimizu, K; Yamamoto, S; Yoshikawa, K | 1 |
2 other study(ies) available for ursolic acid and Clinically Isolated CNS Demyelinating Syndrome
| Article | Year |
|---|---|
Ursolic Acid Enhances Myelin Repair in Adult Mice Brains and Stimulates Exhausted Oligodendrocyte Progenitors to Remyelinate.
Topics: Animals; Anti-Inflammatory Agents; Corpus Callosum; Cuprizone; Demyelinating Diseases; Disease Models, Animal; Glial Fibrillary Acidic Protein; Gliosis; Inflammation; Interleukin-10; Mice; Mice, Inbred C57BL; Myelin Sheath; Oligodendrocyte Precursor Cells; Oligodendroglia; Tumor Necrosis Factor-alpha; Ursolic Acid | 2022 |
Ursolic acid treatment suppresses cuprizone-induced demyelination and motor dysfunction via upregulation of IGF-1.
Topics: Administration, Oral; Animals; Cuprizone; Demyelinating Diseases; Disease Models, Animal; Gene Expression; Insulin-Like Growth Factor I; Mice; Motor Activity; Multiple Sclerosis; Triterpenes; Up-Regulation; Ursolic Acid | 2020 |